N/A
Completed N=110
Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia
Renal Anemia of Chronic Kidney Disease
Source: ClinicalTrials.gov NCT02625844 ↗
Enrolled (actual)
110
Serious AEs
—
Results posted
Mar 2016
Primary outcomePrimary: Average Observed Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents (ESAs) — 38; 15; 17; 5 hours/year
Summary
This study is to document the time spent by health care personnel on anemia-related tasks, including preparation, distribution and administration of monopegylated epoetin beta (Mircera) or other erythropoiesis-stimulating agents (ESAs) in patients with end stage renal disease in hemodialysis centers in Croatia. The total average time will be determined for the same number of patients on monopegylated epoetin beta and patients on other ESAs. In addition, qualitative information will be obtained on changes in practice patterns that may have occurred with the introduction of monopegylated epoetin beta.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Observed Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents (ESAs) |
38; 15; 17; 5; 143; 39 | — |
Eligibility Criteria
Inclusion Criteria
- Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients
Exclusion Criteria
- Hypersensitivity to the active substance or to any of the excipients
- Uncontrolled hypertension
Data sourced from ClinicalTrials.gov (NCT02625844). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.